CN100415770C - 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物 - Google Patents

2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物 Download PDF

Info

Publication number
CN100415770C
CN100415770C CNB028108132A CN02810813A CN100415770C CN 100415770 C CN100415770 C CN 100415770C CN B028108132 A CNB028108132 A CN B028108132A CN 02810813 A CN02810813 A CN 02810813A CN 100415770 C CN100415770 C CN 100415770C
Authority
CN
China
Prior art keywords
phenyl
amino
methyl
butyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028108132A
Other languages
English (en)
Chinese (zh)
Other versions
CN1512999A (zh
Inventor
P·菲雷
V·瓜尼亚诺
P·因巴赫
M·兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113096A external-priority patent/GB0113096D0/en
Priority claimed from GB0129394A external-priority patent/GB0129394D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1512999A publication Critical patent/CN1512999A/zh
Application granted granted Critical
Publication of CN100415770C publication Critical patent/CN100415770C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB028108132A 2001-05-30 2002-05-29 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物 Expired - Fee Related CN100415770C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0113096A GB0113096D0 (en) 2001-05-30 2001-05-30 Organic compounds
GB0113096.2 2001-05-30
GB0129394.3 2001-12-07
GB0129394A GB0129394D0 (en) 2001-12-07 2001-12-07 Organic compounds

Publications (2)

Publication Number Publication Date
CN1512999A CN1512999A (zh) 2004-07-14
CN100415770C true CN100415770C (zh) 2008-09-03

Family

ID=26246132

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028108132A Expired - Fee Related CN100415770C (zh) 2001-05-30 2002-05-29 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物

Country Status (11)

Country Link
US (2) US6933290B2 (https=)
EP (1) EP1399468B1 (https=)
JP (1) JP4416501B2 (https=)
CN (1) CN100415770C (https=)
AT (1) ATE317850T1 (https=)
BR (1) BR0210112A (https=)
CA (1) CA2446282A1 (https=)
DE (1) DE60209227T2 (https=)
ES (1) ES2258149T3 (https=)
PT (1) PT1399468E (https=)
WO (1) WO2002096933A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209227T2 (de) * 2001-05-30 2006-08-17 Novartis Ag 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
SI2495016T1 (sl) 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
AU2007357338B2 (en) 2007-08-06 2014-03-20 Takeda Pharmaceutical Company Limited Proteasome inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CA2727862C (en) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2365809B8 (en) 2008-11-12 2018-10-10 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CA2791651C (en) * 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011133479A2 (en) 2010-04-19 2011-10-27 Niiki Pharma Inc. Combination therapy with a proteasome inhibitor and a gallium complex
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
CN103421032B (zh) * 2012-05-17 2016-01-20 上海创诺制药有限公司 一种硼替佐米中间体及其制备方法和应用
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
CN1121077A (zh) * 1994-06-22 1996-04-24 阿迪尔公司 衍生自二羟硼烷的新颖肽化合物，制备它们的方法以及含有这类化合物的药物组合物
US5780454A (en) * 1994-10-28 1998-07-14 Proscript, Inc. Boronic ester and acid compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
CN1282242A (zh) 1997-12-16 2001-01-31 赛福伦公司 多相催化蛋白酶抑制剂用作抗肿瘤剂
DE60209227T2 (de) * 2001-05-30 2006-08-17 Novartis Ag 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
CN1121077A (zh) * 1994-06-22 1996-04-24 阿迪尔公司 衍生自二羟硼烷的新颖肽化合物，制备它们的方法以及含有这类化合物的药物组合物
US5780454A (en) * 1994-10-28 1998-07-14 Proscript, Inc. Boronic ester and acid compounds

Also Published As

Publication number Publication date
US20050239716A1 (en) 2005-10-27
DE60209227T2 (de) 2006-08-17
US20040167337A1 (en) 2004-08-26
EP1399468B1 (en) 2006-02-15
CA2446282A1 (en) 2002-12-05
CN1512999A (zh) 2004-07-14
EP1399468A1 (en) 2004-03-24
ATE317850T1 (de) 2006-03-15
US6933290B2 (en) 2005-08-23
PT1399468E (pt) 2006-05-31
BR0210112A (pt) 2004-06-08
ES2258149T3 (es) 2006-08-16
WO2002096933A1 (en) 2002-12-05
JP2005501005A (ja) 2005-01-13
JP4416501B2 (ja) 2010-02-17
DE60209227D1 (de) 2006-04-20

Similar Documents

Publication Publication Date Title
CN100415770C (zh) 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
De Groot et al. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug
AU670381B2 (en) Thrombin inhibitors
KR100879673B1 (ko) 유로키나제와 혈관 형성의 비공유적 억제제
US5710129A (en) Inhibitors of SH2-mediated processes
CN1636994B (zh) 制备疏水性磺酰胺碱金属盐的方法以及由此制得的碱金属盐
EP2575467B1 (en) Macrocyclic compounds useful as inhibitors of histone deacetylases
JP2020189847A (ja) ペプチド及びペプチド関連化合物の高浸透性プロドラッグ組成物
RO119413B1 (ro) Derivaţi izosteri ai substratului aspartat proteazei, sărurile lor, compoziţii farmaceutice şi utilizare
CA2370245A1 (en) Enzyme-activated anti-tumor prodrug compounds
CN101563359A (zh) 作为转谷氨酰胺酶抑制剂的迈克尔系统
JP2002521386A (ja) ウロキナーゼおよび血管形成のインヒビター
CN102985439A (zh) Iap bir结构域结合化合物
JPH10508034A (ja) βシート模倣物および生物学的に活性なペプチドまたはタンパク質のインヒビターとしてのその使用
KR20000029838A (ko) 프로테아제및키나제억제제로서그리고전사인자억제제로서의베타-시트유사체의용도
CZ277998A3 (cs) Inhibitory serinproteázy a farmaceutický prostředek
Salib et al. Cyclic hexapeptide dimers, antatollamides A and B, from the ascidian Didemnum molle. A tryptophan-derived auxiliary for L-and D-amino acid assignments
EP3168288B1 (en) Fluorescent probe for detecting dipeptidyl peptidase iv
US20220017538A1 (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
WO1997031016A2 (en) New inhibitors of sh2-mediated processes
JPH11514378A (ja) トロンビン阻害剤
US20250179119A1 (en) Cyclic peptide or salt thereof, and mdmx inhibitor
US20030166572A1 (en) 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives
NZ517603A (en) Azacycloalkanone serine protease inhibitors
CA3093110A1 (en) Prodrug-type anticancer agent using cancer-specific enzymatic activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080903

Termination date: 20110529